Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | — | OT |
patient was accidentally given MENQUADFI, earlier than scheduled with no reported AE; Initial information received on 11-Feb-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 18 years old female patient who was accidentally given Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] earlier than scheduled with no reported ae (adverse event). The patient's past vaccination(s) included MENACTRA on 22-JAN-2018 with dose 1. The patient's past medical history, medical treatment(s) and family history were not provided. On 10-Mar-2023, the patient received a dose 2 of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine Solution for injection (strength, dose, batch and expiry date unknown) via unknown route in unknown administration site for Immunization. On 11-Feb-2025was accidentally given menquadfi dose 3, Solution for injection, dose 0.5 ml1x(once) lot U8369BA expiry- 31-MAR-2028 via intramuscular route in the left deltoid, earlier than scheduled with no reported ae (inappropriate schedule of product administration) (latency same day). Information on batch number and expiry date corresponding to the one at time of event occurrence was requested. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.